Amylyx Pharmaceuticals, Inc. (AMLX)
NASDAQ: AMLX · Real-Time Price · USD
8.50
-0.80 (-8.60%)
Aug 25, 2025, 4:00 PM - Market closed
Amylyx Pharmaceuticals Employees
Amylyx Pharmaceuticals had 123 employees as of December 31, 2024. The number of employees decreased by 261 or -67.97% compared to the previous year.
Employees
123
Change (1Y)
-261
Growth (1Y)
-67.97%
Revenue / Employee
n/a
Profits / Employee
-$1,525,203
Market Cap
757.92M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 123 | -261 | -67.97% |
| Dec 31, 2023 | 384 | 122 | 46.56% |
| Dec 31, 2022 | 262 | 57 | 27.80% |
| Dec 31, 2021 | 205 | 171 | 502.94% |
| Dec 31, 2020 | 34 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
AMLX News
- 18 days ago - Amylyx Pharmaceuticals, Inc. (AMLX) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 19 days ago - Amylyx Pharmaceuticals Reports Second Quarter 2025 Financial Results - Business Wire
- 25 days ago - Amylyx Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 7, 2025 - Business Wire
- 5 weeks ago - Amylyx Pharmaceuticals: A High-Risk Pipeline With Strong Upside Potential - Seeking Alpha
- 6 weeks ago - Amylyx Drug Slashes Sugar Spikes Post-Weight Loss Surgery - Benzinga
- 6 weeks ago - Amylyx Pharmaceuticals Presents New Exploratory Analyses from Phase 2 and Phase 2b Clinical Trials of Avexitide in Post-Bariatric Hypoglycemia at ENDO 2025 - Business Wire
- 7 weeks ago - Amylyx Pharmaceuticals to Host Event to Discuss Post-bariatric Hypoglycemia and Avexitide at ENDO 2025 - Business Wire
- 2 months ago - Amylyx Eyes $2B Opportunity In Post-Surgery Sugar Crash Market - Benzinga